EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Nanometerizing Taxifolin Into Selenized Liposomes to Ameliorate Its Hypoglycemic Effect by Optimizing Drug Release and Bioavailability

Chunli Qi, Huijie Xing, Ning Ding, Weifeng Feng, Yongyi Wu, Xingwang Zhang iD, Yigang Yu

International Journal of Nanomedicine · 2025

DOI: 10.2147/ijn.s510378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025. Verfasst von Chunli Qi und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Food Science and Engineering, South China University of Technology, Guangzhou, 510641, People's Republic of China. Hauptthemen laut MEDLINE: Liposomes, Quercetin, Hypoglycemic Agents, Selenium. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Diabetes mellitus (DM) remains a significant health challenge, with traditional treatments often failing to provide lasting solutions. Taxifolin (Tax), a potential phytomedicine with antioxidant and anti-hyperglycemic properties, suffers from low water solubility and poor bioavailability, necessitating advanced delivery systems. This study aims to nanometerize taxifolin (Tax) into selenized liposomes (Tax-Se@LPs) for enhanced oral delivery and hypoglycemic effect.

Methods

Tax-Se@LPs were fabricated through a thin-film hydration/in situ reduction technique. The resulting nanomedicine was characterized through in vitro release studies, pharmacokinetic and pharmacodynamic evaluations, cellular uptake assays, and formulation stability tests.

Results

The optimized Tax-Se@LPs demonstrated an average particle size of 185.3 nm and an entrapment efficiency of 95.25% after optimization. In vitro release studies revealed that Tax-Se@LPs exhibited a slower and more sustained release profile compared to conventional liposomes, favoring gastrointestinal drug absorption. Pharmacokinetic evaluations in normal rats indicated that Tax-Se@LPs achieved a relative bioavailability of 216.65%, significantly higher than Tax suspensions and unmodified liposomes. Furthermore, in diabetic GK rats, Tax-Se@LPs resulted in a maximal blood glucose reduction of 46.8% and exhibited a more sustained therapeutic duration compared to other formulations. Cellular uptake tests manifested that selenization altered the internalization mechanisms of liposomes while preserving their absorption aptness by intestinal epithelial cells. The physiological and in vitro stability of Tax-Se@LPs was also reinforced by selenization.

Conclusion

Overall, Tax-Se@LPs not only improve the oral bioavailability of Tax but also enhance its therapeutic efficacy. These findings underscore the potential of Tax-Se@LPs as a promising therapeutic strategy for DM management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiposomesQuercetinHypoglycemic AgentsSeleniumAnimalsBiological AvailabilityRatsDrug LiberationMaleHumansParticle SizeDiabetes Mellitus, ExperimentalBlood GlucoseAdministration, OralCaco-2 Cells

Stichwörter der Autor:innen

bioavailabilitydiabetes mellitushypoglycemic effectliposomesseleniumtaxifolin

Substanzen

LiposomesQuercetintaxifolinHypoglycemic AgentsSeleniumBlood Glucose

Autor:innen und Institutionen

  • School of Food Science and Engineering, South China University of Technology, Guangzhou, 510641, People's Republic of China.
  • Institute of Laboratory Animals, Jinan University, Guangzhou, 510632, People's Republic of China.
  • Key Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, 510632, People's Republic of China.
  • Department of Animal, Plant and Food, Guangzhou Customs Technology Center, Guangzhou, 510623, People's Republic of China.
  • Department of Traditional Chinese Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, People's Republic of China.
  • Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510080, People's Republic of China.

ORCID-Profile: Xingwang Zhang

Zitieren

APA

Qi, C., Xing, H., Ding, N., Feng, W., Wu, Y., Zhang, X., & Yu, Y. (2025). Nanometerizing Taxifolin Into Selenized Liposomes to Ameliorate Its Hypoglycemic Effect by Optimizing Drug Release and Bioavailability. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s510378

Vancouver

Qi C, Xing H, Ding N, Feng W, Wu Y, Zhang X, et al. Nanometerizing Taxifolin Into Selenized Liposomes to Ameliorate Its Hypoglycemic Effect by Optimizing Drug Release and Bioavailability. International Journal of Nanomedicine. 2025. doi:10.2147/ijn.s510378

BibTeX
@article{Qi2025,
  author = {Qi, Chunli and Xing, Huijie and Ding, Ning and Feng, Weifeng and Wu, Yongyi and Zhang, Xingwang and Yu, Yigang},
  title = {Nanometerizing Taxifolin Into Selenized Liposomes to Ameliorate Its Hypoglycemic Effect by Optimizing Drug Release and Bioavailability},
  journal = {International Journal of Nanomedicine},
  year = {2025},
  doi = {10.2147/ijn.s510378}
}
Kostenlos starten →